A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2002
10/24/2002	WO2002083898A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	WO2002083891A2 Nucleic acids for inhibiting hairless protein expression and methods of use thereof
10/24/2002	WO2002083879A2 Immunotherapy based on dendritic cells
10/24/2002	WO2002083874A2 Endothelial cell expression patterns
10/24/2002	WO2002083873A2 Enzymes
10/24/2002	WO2002083733A2 Polynucleotides and polypeptides of the ifnalpha-6 gene
10/24/2002	WO2002083709A2 Kinases and phosphatases
10/24/2002	WO2002083704A1 Vascular endothelial growth factor 2
10/24/2002	WO2002083700A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	WO2002083696A2 Novel cyclo azaphospha hydrocarbons
10/24/2002	WO2002083693A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity
10/24/2002	WO2002083668A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	WO2002083667A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	WO2002083664A1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083663A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
10/24/2002	WO2002083645A1 Novel compounds
10/24/2002	WO2002083643A1 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
10/24/2002	WO2002083642A1 Compounds useful as anti-inflammatory agents
10/24/2002	WO2002083628A1 1,4-disubstituted benzo-fused compounds
10/24/2002	WO2002083627A2 Ligands des integrins avss6
10/24/2002	WO2002083624A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
10/24/2002	WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002	WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002	WO2002083155A1 Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis
10/24/2002	WO2002083143A1 Cxcr3 antagonists
10/24/2002	WO2002083122A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	WO2002083121A1 Compositions for improving skin environment and clothes thereof
10/24/2002	WO2002083120A2 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	WO2002083104A1 An effervescent solid composition of matter
10/24/2002	WO2002083088A1 Methods of preventing uvb-induced skin damage
10/24/2002	WO2002083087A1 Sugar intake promoters
10/24/2002	WO2002083084A1 Nail compositions and methods of administering same
10/24/2002	WO2002083066A2 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	WO2002083065A2 Peptide antiangiogenic drugs
10/24/2002	WO2002076470A8 External skin compositions
10/24/2002	WO2002062310B1 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002044271A3 Surfactant-containing cosmetic, dermatological and pharmaceutical agents
10/24/2002	WO2002043689A3 Cosmetic, pharmaceutical and dermatological products
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002032397A9 Electroprocessing in drug delivery and cell encapsulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001072315A9 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract
10/24/2002	WO2001070210A3 Methods for improving size and appearance of a wound
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	US20020156498 Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156203 Sterilized cyanoacrylate solutions containing thickeners
10/24/2002	US20020156129 Method of treating pruritus and a pharmaceutical composition for the method
10/24/2002	US20020156122 Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156042 Human suppressor tRNA oligonucleotides and methods of use for same
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156029 A kit for treating transient acantholytic dermatitis, acne miliaris necrotica, acne varioliformis, perioral dermatitis, or acneiform eruptions comprising, e.g., ivermectin, and a carrier
10/24/2002	US20020156027 Ketolide antibiotics
10/24/2002	US20020156024 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
10/24/2002	US20020156001 Novel fibroblast growth factor ( FGF23) and methods for use
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155991 Polyamino acid derivtive is applied to skin to improve the "camouflaging" and/or fading out of the wrinkles and/or fine lines already formed
10/24/2002	US20020155988 Uses of transport proteins
10/24/2002	US20020155134 Dermatomycosis vaccine
10/24/2002	US20020155126 Pharmacological composition containing yeast cell wall fraction
10/24/2002	US20020155076 Cosmetic or dermatological application
10/24/2002	US20020155072 Use of polyurethanes for improving the water resistance of cosmetic or dermatological formulations
10/24/2002	US20020155069 Applying treatment products simultaneously to a localized area of human body as a function of characteristics of localized area and/or of predetermined design, in order to obtain a mixture of treatment products directly on localized area
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	DE10113604A1 Verfahren zur Spaltung des humanen Wachstumshormons GH A process for cleavage of human growth hormone GH
10/24/2002	CA2763637A1 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2446093A1 Methods of preventing uvb-induced skin damage
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444481A1 Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443733A1 Peptide antiangiogenic drugs
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443563A1 Nail compositions and methods of administering same
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443471A1 An effervescent solid composition of matter
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1250927A2 Pharmaceutical composition for topical application comprising nifedipine
10/23/2002	EP1250917A2 Compositions for the control of microorganisms, comprising primary and secondary esters of polyglycerol in an effective ratio
10/23/2002	EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product
10/23/2002	EP1250358A1 Therapeutic peptides
10/23/2002	EP1250331A1 Formulation for protection against oxidative stress containing benzofuranone derivatives
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments

1 ... 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 ... 1065